Medicare Enrolled

Dr. Durga Borkar, M.D.

Ophthalmology · Philadelphia, PA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Speaking/Promotional
840 WALNUT ST STE 1020, Philadelphia, PA 19107
8003316634
In practice since 2013 (13 years)
NPI: 1063851160 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Borkar from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Borkar? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Borkar

Dr. Durga Borkar is an ophthalmology specialist in Philadelphia, PA, with 13 years of NPI registration. Based on federal Medicare data, Dr. Borkar performed 4,440 Medicare services across 867 unique beneficiaries.

Between the years covered by Open Payments, Dr. Borkar received a total of $119,714 from 24 pharmaceutical and/or device companies across 145 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in ophthalmology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Borkar is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 13 years in practice ▲ Top 19% volume in PA $119,714 industry payments

Medicare Practice Summary

Medicare Utilization ↗
4,440
Medicare services
Top 19% in PA for ophthalmology
867
Unique beneficiaries
$87
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~342 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Eye injection (Vabysmo/faricimab)
An injection of faricimab-svoa, a medication administered in 0.1 mg doses.
2,472 $29 $72
Retinal imaging (OCT scan)
This procedure involves imaging the retina to visualize its structure. It is used to examine the back of the eye.
740 $28 $172
Aflibercept eye injection (Eylea) 326 $691 $1,442
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
266 $84 $255
Eye injection for retinal disease
A procedure involving the administration of medication directly into the eye.
264 $84 $933
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
198 $58 $172
Bevacizumab injection, 10 mg
Administration of a 10 mg dose of bevacizumab medication via injection.
90 $56 $150
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
43 $109 $390
Retinal photography (fundus photo)
This procedure involves taking photographs of the retina, the light-sensitive tissue at the back of the eye. It is used to document the condition of the eye's interior structures.
21 $21 $189
Ultrasound of eye tissue and structures
A diagnostic imaging test that uses sound waves to create pictures of the eye's internal tissues and structures.
20 $32 $371
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$119,714
Total received (2018-2024)
Avg $17,102/year across 7 years
Top 2% in PA for ophthalmology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
24
Companies
145
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$73,670 (61.5%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$39,831 (33.3%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,212 (5.2%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$81,495
2023
$20,355
2022
$9,539
2021
$348
2020
$222
2019
$5,803
2018
$1,951

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Astellas Pharma US Inc
$61,653
Apellis Pharmaceuticals, Inc.
$4,914
Regeneron Pharmaceuticals, Inc.
$4,602
EyePoint Pharmaceuticals US, Inc.
$3,779
F. Hoffmann-La Roche AG
$3,371
Astellas Pharma Global Development
$2,036
Ocular Therapeutix, Inc.
$443
ABBVIE INC.
$364
Genentech, Inc.
$170
Biogen, Inc.
$84
Bausch & Lomb Americas Inc.
$80
Top 3 companies account for 87.3% of 2024 payments
All-time payments by company (2018-2024) ›
Astellas Pharma US Inc
$73,670
Genentech USA, Inc.
$9,652
ABBVIE INC.
$8,130
Regeneron Pharmaceuticals, Inc.
$6,881
F. Hoffmann-La Roche AG
$5,970
Apellis Pharmaceuticals, Inc.
$4,914
EyePoint Pharmaceuticals US, Inc.
$4,115
Astellas Pharma Global Development
$2,036
GLAUKOS CORPORATION
$1,225
Ocular Therapeutix, Inc.
$554
Genentech, Inc.
$551
Regeneron Healthcare Solutions, Inc.
$321
Bausch & Lomb Americas Inc.
$234
AbbVie Inc.
$232
Heidelberg Engineering, Inc.
$205
Dutch Ophthalmic, USA
$150
Carl Zeiss Meditec, Inc.
$142
Novartis Pharmaceuticals Corporation
$141
Alcon Vision LLC
$136
Alcon Laboratories Inc
$129
AbbVie, Inc.
$101
Biogen, Inc.
$84
Bausch & Lomb, a division of Bausch Health US, LLC
$80
Glaukos Corporation
$61
Top 3 companies account for 76.4% of all-time payments
Associated products mentioned in payments ›
ALPHAGAN P · ARTEVO 800 · BYOOVIZ · Constellation · DEXTENZA · DEXYCU · DURYSTA · EVA · EYLEA · EYLEA AFLIBERCEPT INJECTION · EYLEA HD · EYP-1901 · Humira · Izervay · LUMIGAN · Lucentis · OZURDEX · RETISERT · Spectralis · Syfovre · Vabysmo · XIPERE · YUTIQ · combined machine · iStent inject Trabecular Micro-Bypass Stent System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (62%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in ophthalmology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for ophthalmology in PA.

Looking for an ophthalmology specialist in Philadelphia?
Compare ophthalmologists in the Philadelphia area by procedure volume, costs, and industry payment transparency.
Browse ophthalmologists nearby

Geographic Context

Ophthalmologists within 10 mi
531
Per 100K population
33.6
County median income
$60,698
Nearest hospital
THOMAS JEFFERSON UNIVERSITY HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Borkar is a mixed practice specialist, with above-average Medicare volume (top 19% in PA), with speaking/promotional industry engagement in the top 2% of PA peers.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Borkar experienced with eye injection (vabysmo/faricimab)?
Based on Medicare claims data, Dr. Borkar performed 2,472 eye injection (vabysmo/faricimab) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Borkar receive payments from pharmaceutical companies?
Yes. Dr. Borkar received a total of $119,714 from 24 companies across 145 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Borkar's costs compare to other ophthalmologists in Philadelphia?
Dr. Borkar's average Medicare payment per service is $87. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Borkar) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →